J&J diabetic foot gel undergoes FDA safety review

03/28/2008 | CNNMoney · Reuters

The FDA will conduct a safety review of Johnson & Johnson's Regranex after a study found a potential link between the diabetic foot gel and a higher risk of cancer-related deaths. A J&J spokeswoman said the company is working with the FDA and remains "confident in the safety and effectiveness" of the product.

View Full Article in:

CNNMoney · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC